PHARMARON Falls Over 3% Following 8.5% Discounted Share Placement
Stock Performance: PHARMARON (03759.HK) opened down 3.37% and is currently trading at $24, reflecting a 3.77% decrease with significant trading volume of 6.4042 million shares.
New Share Placement: The company announced a placement of approximately 58.4408 million new H shares at an 8.5% discount, aiming to raise nearly $1.32 billion in net proceeds.
Trade with 70% Backtested Accuracy
Analyst Views on 03759
About the author
PHARMARON Jumps Over 12% Following Production Partnership with Eli Lilly for Orforglipron
Stock Performance: PHARMARON's stock surged 12.6% to $20.94 in early Hong Kong trading, reaching a peak of $21.06 during the session.
Short Selling Data: The company experienced short selling of $826.45K, with a short selling ratio of 1.703%.
Partnership Announcement: PHARMARON announced a production cooperation agreement with Eli Lilly for the oral small-molecule GLP-1 receptor agonist, Orforglipron.
Investment Details: Eli Lilly is set to invest $200 million in PHARMARON to enhance its technological capabilities, with plans for future expansion of the partnership.
<Research>CLSA Prefers CDMOs for Earnings Clarity, Recommends WUXI APPTEC, WUXI BIO, and PHARMARON as Top Choices
AI Impact on CRO/CDMO Sector: Investors are shifting focus towards AI disintermediating middlemen, with expectations that integrated CRDMO platforms will benefit more from AI than specialized CROs, which may face mixed effects from internal AI adoption.
CDMO Preference: CLSA favors CDMOs over CROs for better earnings visibility due to their capacity locking capabilities and long-term projects, with WUXI APPTEC, WUXI BIO, and PHARMARON highlighted as top picks in the sector.
Citi Begins 90-Day Positive Catalyst Monitoring on PHARMARON with Buy Rating
Citi's Positive Catalyst Watch: Citi has initiated a 90-day positive catalyst watch on PHARMARON (03759.HK), highlighting upcoming announcements of last year's full-year results and accelerated order growth as key factors for optimism.
Buy Rating and Target Price: The broker has assigned a Buy rating to PHARMARON with a target price of HKD45, recognizing it as a global leader in drug research and development, particularly benefiting from the growth of China's CRO industry.
Expansion into New Areas: PHARMARON is not only maintaining its leadership in drug research but is also expanding into late-stage clinical development, commercial production, and the biopharmaceutical sector.
Market Activity: As of the latest data, short selling for PHARMARON stands at $7.59M with a ratio of 5.753%, indicating some market activity around the stock.
S&P Global Market Intelligence Reveals Recent Top 10 Most Shorted Stocks in Hong Kong (Table)
Top Shorted Stocks: S&P Global Market Intelligence identified the ten most shorted stocks in Hong Kong, with metrics based on the short selling ratio, which measures shares lent out relative to total issued shares.
Leading Stocks: COSCO SHIP HOLD topped the list with a short selling ratio of 40.396%, followed by DONGFANG ELEC and PHARMARON with ratios of 19.528% and 34.783%, respectively.
Stock Performance: The report includes recent price changes and short selling amounts, indicating varying performance among the listed stocks over the past week.
Market Insights: The data reflects investor sentiment and market dynamics, with significant short selling activity observed in companies like PING AN and ZTE, highlighting potential concerns or speculation in the market.
PHARMARON Falls Over 3% Following 8.5% Discounted Share Placement
Stock Performance: PHARMARON (03759.HK) opened down 3.37% and is currently trading at $24, reflecting a 3.77% decrease with significant trading volume of 6.4042 million shares.
New Share Placement: The company announced a placement of approximately 58.4408 million new H shares at an 8.5% discount, aiming to raise nearly $1.32 billion in net proceeds.
PHARMARON Sells Shares at 8.5% Discount to Generate Approximately HKD1.32 Billion Net
Share Placement Announcement: Pharmaron plans to issue approximately 58.44 million new H-shares at HKD22.82 each, representing about 3.19% of its enlarged issued share capital and a 16.57% of total issued H-shares, at an 8.5% discount to the previous closing price.
Use of Proceeds: The company anticipates raising around HKD1.334 billion from the placement, with about 70% allocated for enhancing laboratory service facilities, drug process development, and production facilities.
PHARMARON Jumps Over 12% Following Production Partnership with Eli Lilly for Orforglipron
Stock Performance: PHARMARON's stock surged 12.6% to $20.94 in early Hong Kong trading, reaching a peak of $21.06 during the session.
Short Selling Data: The company experienced short selling of $826.45K, with a short selling ratio of 1.703%.
Partnership Announcement: PHARMARON announced a production cooperation agreement with Eli Lilly for the oral small-molecule GLP-1 receptor agonist, Orforglipron.
Investment Details: Eli Lilly is set to invest $200 million in PHARMARON to enhance its technological capabilities, with plans for future expansion of the partnership.
<Research>CLSA Prefers CDMOs for Earnings Clarity, Recommends WUXI APPTEC, WUXI BIO, and PHARMARON as Top Choices
AI Impact on CRO/CDMO Sector: Investors are shifting focus towards AI disintermediating middlemen, with expectations that integrated CRDMO platforms will benefit more from AI than specialized CROs, which may face mixed effects from internal AI adoption.
CDMO Preference: CLSA favors CDMOs over CROs for better earnings visibility due to their capacity locking capabilities and long-term projects, with WUXI APPTEC, WUXI BIO, and PHARMARON highlighted as top picks in the sector.
Citi Begins 90-Day Positive Catalyst Monitoring on PHARMARON with Buy Rating
Citi's Positive Catalyst Watch: Citi has initiated a 90-day positive catalyst watch on PHARMARON (03759.HK), highlighting upcoming announcements of last year's full-year results and accelerated order growth as key factors for optimism.
Buy Rating and Target Price: The broker has assigned a Buy rating to PHARMARON with a target price of HKD45, recognizing it as a global leader in drug research and development, particularly benefiting from the growth of China's CRO industry.
Expansion into New Areas: PHARMARON is not only maintaining its leadership in drug research but is also expanding into late-stage clinical development, commercial production, and the biopharmaceutical sector.
Market Activity: As of the latest data, short selling for PHARMARON stands at $7.59M with a ratio of 5.753%, indicating some market activity around the stock.
S&P Global Market Intelligence Reveals Recent Top 10 Most Shorted Stocks in Hong Kong (Table)
Top Shorted Stocks: S&P Global Market Intelligence identified the ten most shorted stocks in Hong Kong, with metrics based on the short selling ratio, which measures shares lent out relative to total issued shares.
Leading Stocks: COSCO SHIP HOLD topped the list with a short selling ratio of 40.396%, followed by DONGFANG ELEC and PHARMARON with ratios of 19.528% and 34.783%, respectively.
Stock Performance: The report includes recent price changes and short selling amounts, indicating varying performance among the listed stocks over the past week.
Market Insights: The data reflects investor sentiment and market dynamics, with significant short selling activity observed in companies like PING AN and ZTE, highlighting potential concerns or speculation in the market.
PHARMARON Falls Over 3% Following 8.5% Discounted Share Placement
Stock Performance: PHARMARON (03759.HK) opened down 3.37% and is currently trading at $24, reflecting a 3.77% decrease with significant trading volume of 6.4042 million shares.
New Share Placement: The company announced a placement of approximately 58.4408 million new H shares at an 8.5% discount, aiming to raise nearly $1.32 billion in net proceeds.
PHARMARON Sells Shares at 8.5% Discount to Generate Approximately HKD1.32 Billion Net
Share Placement Announcement: Pharmaron plans to issue approximately 58.44 million new H-shares at HKD22.82 each, representing about 3.19% of its enlarged issued share capital and a 16.57% of total issued H-shares, at an 8.5% discount to the previous closing price.
Use of Proceeds: The company anticipates raising around HKD1.334 billion from the placement, with about 70% allocated for enhancing laboratory service facilities, drug process development, and production facilities.
